Citation Impact
Citing Papers
Preferential induction of apoptosis for primary human leukemic stem cells
2002
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
2010
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
A Meta-Analysis of Cytokines in Major Depression
2009 Standout
Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder
2007
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
2018
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Hepatocellular carcinoma
2003 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
X4 and R5 HIV-1 Have Distinct Post-entry Requirements for Uracil DNA Glycosylase during Infection of Primary Cells
2010 StandoutNobel
Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: A systematic review
2015
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Quality of life: patients and doctors don't always agree: a meta-analysis
2004
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
The Ubiquitin Proteasome System in Neurodegenerative Diseases
2003 StandoutNobel
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Bortezomib inhibits human osteoclastogenesis
2007
Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis
2009 Standout
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
2010
Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies
2011 Standout
Carcinocythemia as the single extension of breast cancer: Report of a case and review of the literature
2001
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
2008
Hepatobiliary surgery
2000
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Colorectal cancer
2013 Standout
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
2007
Colorectal cancer prevention and treatment
2000
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
1999
Understanding the mechanisms and treatment options in cancer cachexia
2012
Colorectal cancer
2019 Standout
Cancer-associated cachexia
2018 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Cetuximab for the Treatment of Colorectal Cancer
2007
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Treatment of nausea and vomiting: Gaps in our knowledge
2006
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy
2003
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
The proteasome: structure, function, and role in the cell
2003
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
The operation of the century: total hip replacement
2007 Standout
Sarcopenia
2019 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Multiple myeloma: evolving genetic events and host interactions
2002
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
2002 Standout
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
1999
Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis
2004
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
The PI3K Pathway in Human Disease
2017 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
A systematic review of health-related quality of life instruments in patients with cancer cachexia
2013
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
2003
Characterization of Amplifiable, Circulating RNA in Plasma and Its Potential as a Tool for Cancer Diagnostics
2004
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
The proteasome: a novel target for anticancer therapy
2006
Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
2007
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Honokiol: A Review of Its Anticancer Potential and Mechanisms
2019
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer
1999
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
2001
Multiple Myeloma
2011 Standout
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)
2005
Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen
1999
Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase
2006
Works of Kurt Possinger being referenced
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
2003
Detection of Amplifiable Messenger RNA in the Serum of Patients with Lung Cancer
2001
Biomarkers of depression in cancer patients
2006
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
1998
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
2005
Proteasome: an emerging target for cancer therapy
2005
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function
2005
Bone resorption parameters [carboxy‐terminal telopeptide of type‐I collagen (ICTP), amino‐terminal collagen type‐I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma
2002
Proteasome inhibitors induce caspase‐dependent apoptosis and accumulationof p21WAF1/Cip1 in human immatureleukemic cells
2000
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer
2008
Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
2006
Fulminant Intravascular Disseminating Malignant Melanoma Mimicking Acute Leukemia
1999
Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients
2003
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
2002
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
2003
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
2008
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
2001
Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes
2002